Schrodinger, Inc. ( ($SDGR) ) has released its Q3 earnings. Here is a breakdown of the information Schrodinger, Inc. presented to its investors.

Receive emails about upcoming NOVA programs and related content, as well as featured reporting about current events through a science lens. That may come as a surprise to those who associate ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed ...

Eli Lilly has joined Schrödinger’s growing stable of drug development partners, putting up $425 million in milestones to access small-molecule candidates against an undisclosed target. Schrödinger has ...

Q3 2025 Management View CEO Ramy Farid reported "very solid progress during the third quarter," highlighting total revenue of $54 million, a 54% increase from the third quarter of 2024. Software ...

Schrodinger (NASDAQ:SDGR) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...

Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million. Updates 2025 Financial Guidance. NEW YORK, November 05, 2025--(BUSINESS WIRE)--Schrödinger, Inc.